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Abstract
Introduction: Insulin resistance (IR), a risk factor for the development of cardiovascular disease, is common among
patients with rheumatoid arthritis (RA). Inflammation, and especially tumour necrosis factor alpha (TNFa), has been
associated with IR, and the administration of anti-TNFa agents is suggested to improve insulin sensitivity. However
obesity, a potent contributor to IR, may limit the beneficial effects of anti-TNFa medication on IR. The aim of this
study is to compare the effects of anti-TNFa therapy on IR between normal-weight and obese patients with RA.
Methods: Patients who were normal-weight with IR (N+IR) or obese with IR (O+IR) and had embarked on anti-
TNFa treatment, participated. Assessments included body mass index (BMI), insulin sensitivity (Homeostasis Model
Assessment of insulin resistance, HOMA and the Quantitative Insulin sensitivity Check Index, QUICKI), and RA
disease characteristics before and following six months of anti-TNFa treatment. Their results were compared to
matched (for age, gender, BMI, disease duration and smoking status) normal-weight patients without IR (N-IR) and
obese without IR (N-IR), respectively. In total, 32 patients were assessed for this study, with 8 in each group.
Results: Following six months of treatment, disease activity was significantly reduced in all groups (P < 0.05) to a
similar extent (P for differences between groups > 0.05 in all cases). In the total population, changes in HOMA (mean
reduction at 6 m = -0.2 ± 0.1; P = 0.088) and QUICKI (mean increase at 6 m = 0.03 ± 0.022; P = 0.092) after treatment
were not statistically significant, though a trend towards improvement was observed. However, N+IR patients showed a
significant decrease in HOMA (mean reduction at 6 m = -0.54 ± 0.2; P = 0.002) and increase in QUICKI (mean increase at
6 m = 0.046 ± 0.02; P = 0.011). These changes were significantly different compared to the other groups (P < 0.05 in all
cases). Multivariable analyses showed that the change in Erythrocyte Sedimentation Rate (ESR), and the change in
C-Reactive Protein (CRP) associated with the improvement in HOMA (ESR: F1-7 = 5.143, P = 0.019; CRP: F1-7 = 3.122,
P = 0.022) and QUICKI (ESR: F1-7 = 3.814, P = 0.021; CRP: F1-7 = 2.67; P = 0.041) only in the N+IR group.
Conclusions: Anti-TNFa therapy, through controlling inflammation, seems to improve insulin sensitivity in normal-
weight RA patients with insulin resistance, but is not sufficient to achieving the same beneficial effect in obese RA
patients with insulin resistance.
Introduction
Insulin resistance (IR), is a well established risk factor
for the development of cardiovascular disease (CVD)
[1]. The mechanisms of IR are under intense investiga-
tion; however, a consistent finding of such research is
the close association between IR and inflammation
[2-4]. Tumour necrosis factor alpha (TNFa), a pro-
inflammatory cytokine, is thought to be one of the main
mediators of IR [2]. Patients with IR exhibit increased
circulating levels of TNFa [5,6], and administration of
TNFa induces IR in healthy individuals [7]. In otherwise
healthy individuals, obesity is a significant contributor to
IR; obesity is a low-grade inflammatory condition [8,9]* Correspondence: antonios.stav@gmail.com1Department of Sport and Exercise Science, University of Thessaly, Trikala-
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and TNFa is also thought to be the link between obesity
and insulin resistance [3].
Rheumatoid arthritis (RA), associates with reduced life
expectancy compared to the general population [10],
mainly due to increased prevalence of CVD, and increased
morbidity and mortality from CVD compared to the gen-
eral population [11-13]. TNFa is central to the develop-
ment and progression of RA and a common therapeutic
target [14]. Apart from disease activity, treatment with
anti-TNFa appears to also improve insulin sensitivity [15]
and to reduce CVD risk in RA [16,17]. However, obesity -
a potent contributor to IR in the general population -
might influence the way anti-TNFa therapy affects IR.
Indeed, in the general population, anti-TNFa does not
improve IR in obese individuals [18]. The aim of this long-
itudinal study was to compare the effects of six months of
anti-TNFa therapy on IR between normal weight and
obese RA patients. Our primary hypothesis was that the
possible beneficial effects of anti-TNFa on IR would be
limited by the presence of obesity.
Materials and methods
Participants
The study was conducted at the Dudley Group NHS
Foundation Trust, UK. It had Research Ethics Committee
approval by the Black Country Ethics Committee and
local R&D approval, and all volunteers provided written
informed consent. Patients with RA, who were either
normal weight with IR (N+IR) or obese with IR (O+IR)
and embarked, for the first time, on clinically-indicated
anti-TNFa treatment were invited to participate. Type of
medication was decided by their managing physician and
dosage was based on NICE guidelines. Patients with dia-
betes mellitus or using anti-diabetic medication were
excluded from the study. The results of the N+IR and O
+IR patients were compared to age, gender, BMI, disease
duration and smoking status matched normal-weight
patients without IR (N-IR) and obese patients without IR
(N-IR), respectively. A total of 32 patients were assessed;
8 in each of the groups: that is, N+IR, O+IR, N-IR and
O-IR. Demographic and disease characteristics appear in
Table 1.
Assessments
Standing height was measured to the nearest 0.5 cm on
a Seca 214 Road Rod portable stadiometer (Seca gmbh &
co. kg., Hamburg, Germany). Body weight was assessed
on a Tanita MA-418 BC body composition analyser
(Tanita Corp., Tokyo, Japan). BMI (kg/m2) was calcu-
lated on the basis of measured height and weight. The
recently published RA-specific BMI cut-off points (that
is, 23 kg/m2 for overweight and 28 kg/m2 for obesity)
were used to classify them as under-, normal-, over-
weight or obese [19].
Glucose and insulin were assessed in venous blood
collected in the fasting state; IR was evaluated using the
Homeostasis Model Assessment of insulin resistance
(HOMA) [20] and the Quantitative Insulin sensitivity
Check Index (QUICKI) [21], and was defined as HOMA
≥2.5 [22] and/or QUICKI ≤0.333 [23,24]. Both methods
correlate well with insulin clamp (HOMA: r = 0.88 [22];
QUICKI: r = 0.78 [21]) and are considered valid calcula-
tions for insulin resistance and insulin sensitivity,
respectively. Smoking status was also recorded.
Inflammatory load was assessed by the erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP).
The Disease Activity Score-28 (DAS28) was used to
assess clinical disease activity [25] and the anglicised ver-
sion of the Stanford Health Assessment Questionnaire
(HAQ) [26] to measure functional disability. Disease
duration was recorded from review of the clinical notes.
All assessments were repeated following six months of
anti-TNFa therapy.
Data management and analyses
The Statistical Package for Social Sciences version 15.0
(SPSS Inc. Chicago, IL, USA) was used for the statistical
analyses. The Kolmogorov-Smirnov test of normality
was used to assess dispersion of the variables. Dispersion
of data is reported as the mean (standard deviation-SD)
as all were normally distributed. Statistical significance
was set at P < 0.05.
T-tests were used to identify differences at baseline in
the assessed variables between N+IR and N-IR as well as
O+IR and O-IR. Repeated measures analysis of variance
(ANOVA) was then used to evaluate the effects of six-
month anti-TNFa treatment on HOMA and QUICKI as
well as BMI, and RA characteristics, and identify differ-
ences between groups in the magnitude of these effects.
Multivariate ANOVA (MANOVA) was then used to
assess the associations between the changes in HOMA
and QUICKI with baseline BMI, RA characteristics (ESR,
CRP, DAS, HAQ), age and gender, as well as the change
in these variables following treatment. Interactions
between baseline BMI and age, disease duration and CRP
were also included in the models.
Results
At baseline, t-tests did not identify any significant differ-
ences between the groups, other than, as expected, in IR
(HOMA and QUICKI; Table 1). Following the six-month
intervention, repeated measures ANOVA found no
changes in BMI in any of the groups (P > 0.05). Inflam-
mation and disease activity were significantly reduced in
all groups (P < 0.05) but to a similar extent (P for differ-
ences between groups > 0.05 in all cases). Overall,
HOMA showed a tendency to reduce (P = 0.088) while
QUICKI a tendency to increase (P = 0.092) (Table 2).
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When patient grouping was introduced as a factor in
the analyses, it was revealed that the treatment resulted
in significant decreases in HOMA (Δ6 m = -0.54; P =
0.002) and increases in QUICKI (Δ6 m = 0.046; P =
0.011) in the N+IR, but not any of the other three groups
(P > 0.05 in all cases). The magnitude of the changes in
IR was significantly different between N+IR and the rest
of the groups (N-IR: HOMA, P = 0.008, QUICKI, P =
0.002; O+IR: HOMA, P = 0.019, QUICKI, P = 0.038; O-
IR: HOMA, P = 0.000, QUICKI, P = 0.001; Figure 1). No
differences in the magnitude of improvements between
the other groups were observed (P > 0.05 for both
HOMA and QUICKI).
Finally, MANOVA indicated that baseline BMI, baseline
RA characteristics, baseline BMI, and the change in BMI
did not associate with the change in HOMA or QUICKI
in any of the groups (P > 0.05 in all cases). However, the
change in ESR and the change in CRP associated with the
improvement in HOMA (ESR: F1-7 = 5.143, P = 0.019;
CRP: F1-7 = 3.122, P = 0.022) and QUICKI (ESR: F1-7 =
3.814, P = 0.021; CRP: F1-7 = 2.67; P = 0.041) only in the
N+IR group.
Retrospective power calculations (a = 0.05) using the
values observed above indicate a power of 0.91 and a
power of 0.88 for the changes observed in HOMA (Δ6
m for N+IR = 0.49, for O+IR = 0.11, common St.D. =
Table 1 Participant characteristics at baseline assessment
Normal Weight (n = 16) Obese (n = 16)
+IR -IR +IR -IR
N (females) 8 (5) 8 (5) 8 (6) 8 (6)
Anti-TNFa agent (Infliximab/Etanercept/Adalimumab) 5/3/0 4/3/1 6/2/0 5/3/0
Smokers (current; ex) 3 (1; 2) 4 (1; 3) 3 (2; 1) 4 (2; 2)
Age (years) 60.8 62.2 58.6 60.8
(6.9) (7.8) (6.7) (8.0)
Height (cm) 165.9 167 165.4 165.2
(10.6) (12.2) (11.9) (9.4)
Weight (kg) 60.3 61.6 88.9 89.8
(6.4) (7.2) (10.1) (9.6)
BMI (kg/m2) 21.8 22.1 32.3 32.8
(2.4) (2.2) (3.0) (3.1)
HOMA 2.9 2.2* 3.1 2.1#
(0.7) (0.4) (0.5) (0.8)
QUICKI 0.29 0.36* 0.30 0.37#
(0.02) (0.03) (0.03) (0.01)
HAQ 1.6 1.8 1.7 2.0
(0.3) (0.2) (0.4) (0.5)
DAS 5.7 5.9 6.2 6.1
(0.7) (0.5) (1.0) (0.6)
ESR (mm/h) 31 38 35 43
(7.5) (10) (9.5) (12.5)
CRP (mg/L) 29 32.5 31.4 34.2
(6.4) (8.2) (8.8) (7.4)
Disease Duration 9.1 8.6 8 10.2
(years) (2.5) (2.3) (3.6) (4.7)
* Significantly different compared to N+IR (P < 0.05). # Significantly different compared to O+IR (P < 0.05). BMI, body mass index; CRP, C-reactive protein; DAS,
disease activity score 28; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; +IR, with insulin resistance; -IR, without insulin resistance;
HOMA, Homeostasis Model Assessment Of Insulin Resistance; QUICKI, Quantitative Insulin Sensitivity Check Index
Table 2 Effects of the treatment on the assessed
variables for all participants
Δ6 m P
BMI (kg/m2) 0.45 ± 0.07 0.466
DAS -2.37 ± 0.4 0.000
HAQ -0.4 ± 0.01 0.001
ESR (mm/h) -18.55 ± 12.8 0.002
CRP (μg/L) -16.1 ± 9.4 0.016
HOMA -0.2 ± 0.1 0.088
QUICKI 0.03 ± 0.022 0.092
Δ6 m, mean difference between baseline and six-month measurement; BMI,
body mass index; CRP, C-reactive protein; DAS, Disease Activity Score 28; ESR,
erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire;
HOMA, Homeostasis Model Assessment Of Insulin Resistance; QUICKI,
Quantitative Insulin Sensitivity Check Index.
Stavropoulos-Kalinoglou et al. Arthritis Research & Therapy 2012, 14:R160
http://arthritis-research.com/content/14/4/R160
Page 3 of 7
0.26) and QUICKI (Δ6 m for N+IR = 0.04, for O+IR =
0.01, common St.D. = 0.02), respectively.
Discussion
The main aim of this study was to compare the effects
of anti-TNFa treatment on insulin sensitivity among
normal weight and obese RA patients. To our knowl-
edge, this is the first study to use such an approach and
indeed to identify different effects of anti-TNFa treat-
ment in normal-weight vs. obese individuals with RA.
Our results indicate a significant improvement of IR
only in normal-weight RA patients with IR but not in
obese RA patients with IR. Reduction in inflammation
was associated with the changes in IR only in the nor-
mal weight but not in obese patients.
Sample size is the main limitation of our study. How-
ever, the number of patients that fulfilled the inclusion
criteria for this study (that is, insulin resistance, anti-
TNFa naive and embarking on anti-TNFa) is limited.
This is also reflected by sample size of other studies
investigating similar hypotheses [15]. In our study, a lar-
ger sample size might have been able to identify
improvements in IR in the O+IR group. This group had
a slight improvement in IR (as shown in Figure 1).
However, this improvement was not statistically signifi-
cant (mean change in HOMA: -0.11; 95% odds ratio:
0.06 to 0.15; and QUICKI: 0.009; 95% odds ratio: 0.004
to 0.018; P > 0.05 for both) or indeed clinically signifi-
cant as both variables remained within the “at risk”
range. Moreover, the statistical test we used (Repeated
measures ANOVA) looks at the differences in the
responses between the two groups, not merely the
response of each group. We, therefore, doubt that a lar-
ger sample size would significantly change the conclu-
sions of the present study. A second limitation of our
study is that we did not control for changes in physical
activity, which may influence IR. However, any such
changes are likely to have occurred throughout all the
subgroups, especially since disease activity was reduced
equally among them. Additionally, for the duration of
the study, no changes in thyroid status were observed
(all patients were euthyroid at baseline), there were no
changes in other anti-rheumatic medication (including
steroids and hydroxychloroquine) or cardio/vasoactive
therapy (including angiotensin-converting-enzyme
(ACE) inhibitors).
Similar studies in RA patients have shown reduction in
IR following anti-TNFa therapy (reviewed in [27]). BMI,
even though assessed, is not reported in some of these
studies [28,29]; in those who report it, observations are
predominantly made on normal-weight to slightly over-
weight patients (BMI: approximately 22 kg/m2 [30] to
approximately 25 kg/m2 [31,32]). Even in these studies
increasing BMI appears to associate with a smaller
improvement in IR [31]. Similarly, acute administration
of anti-TNFa significantly improved insulin sensitivity in
most RA patients; however, this improvement was again
minimised with increasing BMI [33]. We have been able
Figure 1 Changes in HOMA and QUICKI following six months of anti-TNFa treatment. Anti-TNFa treatment significantly improves HOMA
and QUICKI only in the N+IR group. * Significant difference compared to baseline. HOMA, homeostasis model assessment of insulin resistance;
QUICKI, quantitative insulin sensitivity check index; N+IR, normal weight with insulin resistance; N-IR, normal weight without insulin resistance; O
+IR, obese with insulin resistance; O-IR, obese without insulin resistance.
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to find a single case-study of an obese patient with RA
that experienced significantly improved IR following
anti-TNFa treatment [34]; the extremely high baseline
HOMA levels (> 25 with a cut-off for IR at 2.5) of this
patient should be noted.
The reason for this apparent difference in the
responses of lean vs. obese individuals to anti-TNFa is
not yet clear. However, our findings for the obese RA
patients are in line with data from the general popula-
tion. In obese individuals with the metabolic syndrome
[18] or with type 2 diabetes mellitus [35] anti-TNFa
failed to improve IR. It is well established that enlarged
adipose tissue is a source of inflammation. Up to 50% of
its cell mass is monocytes and macrophages. Adipocytes
and macrophages both are a source of inflammatory
cytokines reducing insulin sensitivity of muscle and
increasing plasma concentrations of these compounds
[36,37]. The cytokines TNFa and interleukin-6 (IL-6) in
particular, stimulate both the c-Jun amino-terminal
kinase (JNK) and the IB kinase-b (IKK-b)/nuclear fac-
tor-B (NF-B) pathways, resulting in up-regulation of
potential mediators of inflammation and lead to IR [38].
Other potential pathways by which obesity might induce
IR include the action of retinol-binding protein-4
(RBP4) which reduces phosphatidylinositol-3-OH kinase
(PI(3)K) signalling in muscle and enhances expression of
the gluconeogenic enzyme phosphoenolpyruvate carbox-
ykinase in the liver [39]. The role of IL-6 is of particular
importance in the context of the present study, as this is
not directly targeted by anti-TNFa medication and
could thus be important in maintaining IR in obese
individuals. A final interesting approach to the potential
underlying mechanisms could be the role of the inflam-
masome and, especially, NLRP3 in IR. This is a cytosolic
protein complex leading to the activation of the proces-
sing enzyme caspase-1, which is central to the produc-
tion of Interleukin -1b (IL-1b) [40]. IL-1b has been
recently recognized as a potent instigator of the obesity-
induced inflammation and as such a contributor to IR
[41]. Even though anti-TNFa medication does not
directly target IL-1b, it is implicated in the activation of
NLRP3 [42], thus indirectly affecting IL-1b production.
The associations of obesity, inflammasomes and IL with
IR in RA warrant further investigation.
Adipose tissue also secretes adipokines, such as adi-
ponectin and resistin [43], reduced levels of adiponec-
tin and increased levels of resistin associate with IR
[44,45]. IR and other features of the metabolic syn-
drome independently associate with atherosclerosis in
RA [46]. Adiponectin stimulates fatty acid oxidation via
AMP-activated protein kinase (AMPK) and peroxisome
proliferator activated receptor-a-dependent pathways
[38].
Anti-TNFa treatment may affect levels of these adipo-
kines. In patients with severe RA, refractory to conventional
disease-modifying antirheumatic drug (DMARD) therapy,
periodical treatment with infliximab (an anti-TNFa
blocker) results in a rapid reduction of serum resistin levels
[47]. Serum resistin levels, in these patients, associate with
laboratory markers of inflammation, particularly CRP, but
not with BMI [47]. Moreover, in the same cohort of
patients, an independent negative correlation of high-grade
inflammation with circulating adiponectin concentrations
has been observed [48]. Low adiponectin concentrations
further correlate with atherogenic dyslipidemia and high
plasma glucose [48].
Moreover, anti-TNFa treatment may reduce lipolysis
within the muscle by inhibiting TNFa action locally [43] -
obese individuals have high fat intramuscular content.
This may lead to further increases in intramuscular con-
centration of fatty acid metabolites, such as diacylglycerol,
fatty acyl-coenzyme A, and ceramides, as a result of
increased release of non-esterified fatty acids [39]. This
leads to serine/threonine phosphorylation of insulin recep-
tor substrate-1 and -2, and eventually to insulin resistance
[49].
From a clinical point of view, our findings would suggest
that additional measures to anti-TNFa therapy should be
employed in order to combat IR in obese RA patients.
Weight-loss is probably the primary such measure. How-
ever, due to the lack of weight-loss studies in RA [50] and
the high prevalence of muscle wasting among these
patients [51], any such interventions should be employed
with great care. Exercise, which is known to benefit RA
patients in several ways [52], could possibly prove a valu-
able tool in reducing body weight while maintaining mus-
cle mass and improving insulin sensitivity, but further
research is needed. In addition to IR, such interventions
could improve other CVD risk factors and reduce the high
CVD risk of RA patients.
From the above results, it seems that the effects of anti-
TNFa therapy on IR differ significantly between normal-
weight and obese patients with RA. Such therapy seems to
improve IR in normal-weight but not in the obese RA
patients. In the latter group, obesity-related processes seem
to counteract the potential benefits of anti-TNFa. Further
studies looking at the specific mechanisms by which anti-
TNFa therapy affects IR and the mechanisms by which
obesity interacts in this process should be pursued.
Conclusions
In conclusion, anti-TNFa therapy seems to improve
insulin sensitivity in normal weight RA patients with IR
but not in obese RA patients with IR. It is possible that
the mechanisms leading to insulin resistance are partly
different in normal-weight and obese patients with RA.
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